Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label proof-of-concept study of RZL-012 for reduction of lipoma size
MOH_2018-06-25_002478Phase 2Completed
- Sponsor
- Raziel Therapeutics
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Tapencarium in lipoma (2 arms), sponsored by Raziel Therapeutics. Primary endpoints: Proof of concept for lipoma size reduction and Safety and tolerability. Started May 2018; status: completed.
02
Drugs
Tapencarium
03
Conditions
lipoma
Beyond the preview
Go deeper on MOH_2018-06-25_002478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-06-25_002478.